ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

INVA Innoviva Inc

15.26
0.27 (1.80%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Innoviva Inc INVA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.27 1.80% 15.26 16:16:11
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
15.01 14.98 15.285 15.26 14.99
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202406:00BWInnoviva Specialty Therapeutics’ Positive Phase 3 Oral..
07/3/202418:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202418:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202418:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202417:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202416:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202415:15EDGAR2Form 8-K - Current report
29/2/202415:05BWInnoviva Reports Fourth Quarter and Full Year 2023 Financial..
22/2/202420:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202420:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202406:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202420:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202419:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
17/11/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/11/202307:30EDGAR2Form 8-K - Current report
01/11/202315:30EDGAR2Form 8-K - Current report
01/11/202315:15BWInnoviva Reports Third Quarter 2023 Financial Results and..
01/11/202315:05BWPositive Results Announced in Largest Pivotal Phase 3 Trial..
19/9/202307:30BWInnoviva to Participate in the Cantor Global Healthcare..
18/9/202307:00BWXACDURO®, The First and Only Antibiotic Developed to Target..
31/8/202319:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/8/202312:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202316:24EDGAR2Form 8-K - Current report
25/8/202315:52BWInnoviva Appoints Stephen Basso as Chief Financial Officer
07/8/202315:42EDGAR2Form 8-K - Current report
02/8/202320:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202315:15EDGAR2Form 8-K - Current report
02/8/202315:05BWInnoviva Reports Second Quarter 2023 Financial Results and..
11/7/202307:16EDGAR2Form 8-K - Current report
06/6/202315:05BWInnoviva to Participate in the Goldman Sachs Annual Global..
23/5/202318:10DJNFDA Approves Innoviva's Bacterial Pneumonia Treatment
23/5/202317:42BWInnoviva Specialty Therapeutics Announces FDA Approval for..
11/5/202317:45BWResults from Pivotal Phase 3 ATTACK Trial of Investigational..
09/5/202315:32BWInnoviva Reports First Quarter 2023 Financial Results and..
28/4/202316:30BWInnoviva Announces Retirement of Board Chairman

Su Consulta Reciente

Delayed Upgrade Clock